Consonance Capital Management: A Look at Q2 and Q3 2022 Holdings
Ava Hoppe | 29 April, 2023
As the world of finance continues to change at a rapid pace, Consonance Capital Management LP has been making strategic moves to stay ahead of the curve. In this blog post, we'll examine the firm's Q2 and Q3 2022 13F holdings and analyze the shifts in their investment strategy.
Consonance Capital Management LP is a healthcare investment firm that focuses on making long-term investments in companies that are driving innovation and change. As of Q3 2022, the firm had over $1.8 billion in regulatory assets under management.
Let's take a closer look at the changes in holdings from Q2 to Q3 2022:
Surrozen Inc (SRZN):
In Q2 2022, Consonance Capital Management LP held 3,497,500 shares of Surrozen Inc, with a value of $10,493,000. In Q3 2022, the firm's shares remained unchanged at 3,497,500, with a value of $7,065,000. This represents a decrease of 32.7% in value.
Surrozen Inc Warrants (SRZNW):
Consonance Capital Management LP held 1,165,832 shares of Surrozen Inc Warrants in both quarter two and quarter three 2022, but the value decreased slightly from $223,000 to $215,000, a decrease of 3.6%.
Silence Therapeutics PLC (SLN):
In Q2 2022, Consonance Capital Management LP owned 634,270 shares of Silence Therapeutics PLC, with a value of $7,516,000. In Q3 2022, the firm sold off all of its shares, which means they had no holdings in Silence Therapeutics PLC during the third quarter.
Compass Therapeutics Inc (CMPX):
Like Silence Therapeutics PLC, Compass Therapeutics Inc was sold off by Consonance Capital Management LP in Q3 2022. The firm had previously owned 1,603,789 shares valued at $4,218,000 in Q2 2022.
United Therapeutics Corp Del (UTHR):
Consonance Capital Management LP also sold off its holdings in United Therapeutics Corp Del in Q3 2022, after previously holding 2,998 shares valued at $706,000 in Q2 2022.
Globus Med Inc (GMED):
In Q2 2022, Consonance Capital Management LP held 5,405 shares of Globus Med Inc, with a value of $303,000. However, during Q3 2022, the firm sold off all of its shares, which means they had no holdings in Globus Med Inc during the third quarter.
Tandem Diabetes Care Inc (TNDM):
Like Globus Med Inc, Tandem Diabetes Care Inc was also sold off by Consonance Capital Management LP in Q3 2022. The firm had previously owned 4,294 shares valued at $254,000 in Q2 2022.
In conclusion, Consonance Capital Management LP has made some significant changes to its investment strategy in the healthcare space. While they've looked to maintain their position in high-potential Surrozen Inc, they've completely sold off their holdings in Silence Therapeutics PLC, Compass Therapeutics Inc, United Therapeutics Corp Del, Globus Med Inc, and Tandem Diabetes Care Inc. Only time will tell how these decisions will impact Consonance Capital Management LP's long-term investment success.
Other Posts
- Analyzing Foxhaven Asset Management's Q3 to Q4 2022 Changes in Fund Holdings
- How Prosight Management Is Navigating Q3 to Q4 Changes in Their 13F Holdings
- BTR Capital Management Inc. Q2 2022 vs. Q3 2022: Analyzing the Top 50 Holdings
- Paragon Wealth Strategies, LLC Q2 2023 vs. Q3 2023 13F Holdings Comparison
- Storewise Introduces PriceFind: Empowering Independent Grocers with Hyperlocal Competitive Pricing Insights
- Alpine Investors Raises $4.5 Billion Fund IX to Support Software and Services Companies
- DSM Capital Partners LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison: Which Stocks Are on the Rise?
- FrontFour Capital Group LLC Q2 2019 vs. Q3 2019 13F Holdings Comparison
- St. Johns Investment Management Company, LLC Q2 2023 vs. Q3 2023 13F Holdings Comparison
- The Shifting Tides of Kelman-Lazarov, Inc.: A Comparison of Q3 and Q4 2022 13F Holdings